NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis

Arcutis Biotherapeutics, Inc. (ARQT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ARQT

$23.90

+$0.24 (+1.01%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ARQT with… →

ARQT Key Statistics

As of Sep 4, 2026
Trading
Open
$23.27
Previous Close
$23.66
Day's Range
23.27–24.02
52-Week Range
16.57–31.77
Volume
1.62M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.50
Valuation
Market Cap
$3.00B
P/E Ratio
108.64
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
18.34
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.47
EPS (ttm)Profit attributable to each share over the last twelve months.
0.22
Financials (FY)
Revenue (FY)
$376.07M+91.34%
Net Income (FY)
−$16.14M
Profit marginThe share of revenue left as profit after all costs and taxes.
6.15%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
125.69M
1-Year Return
+47.44%
Dividend and dates
Earnings Date
October 27, 2026
Avg Volume
1.68M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ARQT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−17.70%
2025+108.47%
2024+331.27%
2023−78.18%
2022−28.64%
2021−26.27%
2020+29.04%

As of September 4, 2026.

ARQT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$376.07M−$16.14M−4.3%
2024$196.54M−$140.04M−71.3%
2023$59.61M−$262.14M−439.8%
2022$3.69M−$311.46M−8449.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$376.07M$339.38M−$12.23M−$16.14M−4.3%
2024$196.54M$177.41M−$128.40M−$140.04M−71.3%
2023$59.61M$54.62M−$241.10M−$262.14M−439.8%
2022$3.69M$2.93M−$301.63M−$311.46M−8449.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ARQT Valuation vs Biotechnology Median

Median of 656 stocks
MetricARQTBiotechnology medianvs median
P/E108.6412.578.6x the median
P/S ratio6.4715.2658% below
Profit margin6.15%0.00%6.1 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Arcutis Biotherapeutics, Inc. (ARQT) carries a market capitalisation of $3.00B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 354.

The most recent close on file for ARQT is $23.90, dated September 4, 2026. That is +$0.24 (+1.01%) against the previous close. The 52-week range on file runs from $16.57 to $31.77. The latest close sits 44.24% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $376.07M. That is +91.34% against the prior fiscal year, when revenue was $196.54M. The same year closed with a net loss of $16.14M. The reported profit margin is 6.15%. That is 6.1 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 0.22.

Across the 4 fiscal years on file, revenue moves from $3.69M in 2022 to $376.07M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

ARQT trades at a trailing price-to-earnings ratio of 108.64. That is 8.6 times the Biotechnology median of 12.57. On forward earnings the ratio is 18.34. The price-to-sales ratio is 6.47. On price-to-sales that is 57.58% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 1.5. Annualized volatility over the trailing 6 years is 71.07%. Over the trailing twelve months the price has returned +47.44%. Across 5 years the annualized return works out at +2.00%.

Growth & Income

The record shows no dividend for ARQT.

Across the complete calendar years on file, 2024 returned +331.27% and 2023 returned −78.18%. Of the 6 complete calendar years on file, 3 finished higher. 2026 is still running; the price is −17.70% year to date.

Peer Comparison

Arcutis Biotherapeutics, Inc. (ARQT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Arcutis Biotherapeutics, Inc. ARQT $3.00B 108.6
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Arcutis Biotherapeutics, Inc. trades at a P/E of 108.6.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Visit website →